Sanofi and radioligand partner Orano Med report mid-stage win in rare tumor

Partners Sanofi and Orano Med said on Wednesday that their alpha-emitting radiopharmaceutical candidate succeeded in a Phase 2 study in a rare type of cancer. The trial enrolled patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs), which ...